Poxel SA

7PO

Company Profile

  • Business description

    Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

  • Contact

    259/261 Avenue Jean Jaures
    Immeuble le Sunway
    Lyon69007
    FRA

    T: +33 437372010

    https://www.poxel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,767.28129.680.55%
NASDAQ25,136.27229.82-0.91%
Nikkei 22559,676.001,466.35-2.40%
NZX 50 Index14,303.77130.090.92%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,595.2539.10-1.08%

Market Movers